Home
Amgen Entry Level Jobs

Amgen Entry Level Jobs

July 19, 2022 Uncategorized No Comments

Amgen is a leading global biotechnology company that discovers, develops and delivers innovative medicines for people with serious diseases. We discover, develop and manufacture medicines that help patients restore their health.

Amgen Entry Level Jobs

Amgen is looking for entry-level candidates to join our team as a part of our Research & Development (R&D) team. The R&D team is responsible for developing new drugs and therapies to help patients oncology programs and other therapeutic areas. Our R&D employees are involved in all aspects of drug development from early discovery through to commercialization.

Entry Level R&D Jobs

  • Analytical Scientist – Clinical Chemistry (Trainee)
  • Associate Scientist – Biochemistry (Trainee)
  • Associate Scientist – Toxicology (Trainee)

Amgen Entry Level Jobs

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.[4][5] One of the world’s largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.[6][7] Amgen’s Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County.[8][7][9] Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.[10]

In 2018, the company’s largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. Amgen sponsors the Tour of California.[11]

Contents

AMGen corporate logo, 1983

Argentine president Mauricio Macri meets with heads of Amgen, in 2018

The word AMGen is a portmanteau of the company’s original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company’s first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[12] followed by Kevin W. Sharer in 2000.[13] Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer’s retirement.[14]

The company has made at least five major corporate acquisitions.

Timeline

  • 1980. William Bowes from Cetus Corporation recruits Winston Salser from UCLA to start Amgen with a scientific advisory board consisting of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.[15]
  • 1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure. Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[16]
  • 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[17] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[18]
  • 1998. In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha).[16] A 2006 assessment by the National Institute of Clinical Excellence of the United Kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors “are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints.”[19] A more recent study demonstrated that compared to traditional disease-modifying anti-rheumatic drugs, treatment with etanercept improved survival, reduced cardiovascular events and reduced the incidence of hematological cancers.[20]
  • 2010. On June 6, 2010 Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[21] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[22]
  • 2010 In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[23] The clinical trials primarily enrolled patients with breast or prostate cancer.
  • 2012. Illegal marketing practices. The Los Angeles Times reported on December 18, 2012 that Amgen pleaded guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.[24] Larry Husten, a contributor at Forbes.com elaborates on AMGEN’s illegal marketing practices in this case, namely that the “government accused Amgen of marketing Aranesp for indications not approved by the FDA and other illegal marketing practices”.[25] One of the drugs mentioned in the lawsuit had sales of $492 million in the third quarter of 2012, down 17% from the same quarter the previous year due to “reimbursement problems and label changes”.[26]
  • 2013. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[27] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[28][29]
  • 2015. In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.[30] The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[31][32]
  • 2016. In September, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[33]
  • 2017. Cash returned to shareholders totalled a record $6.5 billion through dividends and share repurchases.[34]
  • 2018. Amgen was ranked 123 on the Fortune 500 list of the largest United States corporations by revenue.[35]
  • 2019. Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities.[36] In August the company announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, as part of Celgene and Bristol-Myers Squibbs merger deal.[37][38] In October, Amgen announced it would be acquiring a 20.5% stake in the Beijing-based BeiGene for $2.7 billion.[39]
  • 2021. In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion[40][41] and Rodeo Therapeutics for up to $720 million.[42] In July, Amgen acquired Teneobio for $900 million

Acquisition history

show

The following is an illustration of the company’s major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Products

Amgen’s approved drugs or therapeutic biologicals include:

Products developed and then sold off

Pipeline and clinical trials

In December 2013, Amgen had 11 drugs in Phase III clinical trials.[46] In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[47] Later in the same week, the company in conjunction with AstraZeneca reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[48]

In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[49]

In June 2015, Amgen presented Phase II clinical trial data for their anti-CGRP antibody AMG 334 for migraine, approved for sale as Aimovig in 2019.[50]

In 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.[51] In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.[52] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[53] and Japan.[54]

Carbon footprint

Amgen reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y)[55] and aims to reach net zero emissions by 2027.[56]

Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
354369292279264249243

Related Posts

About The Author

Gabriella Smile

Leave a Reply